VICAL IL-2 LIPID COMPLEX FOR SOLID TUMORS AND LYMPHOMAS CLEARED BY NIH RAC; GENZYME ADENOVIRUS VECTOR FOR CF WITH AEROSOL ADMINISTRATION ALSO APPROVED
Executive Summary
Vical's gene therapy protocol with interleukin-2 for treatment of solid tumors or lymphomas was approved unanimously with one abstention by NIH's Recombinant DNA Advisory Committee on Dec. 1, pending revisions in the patient informed Consent form.